Anti-tumoral activity of imidazoquines, a new class of antimalarials derived from primaquine

• Type: Article in International Scientific Journal
• Date: 2009

Authors

Iva Fernandes (Author) Other; Nuno Vale (Author) FCUP; Victor de Freitas (Author) FCUP; Rui Moreira (Author) Other; Nuno Mateus (Author) FCUP; Paula Gomes (Author) FCUP

Journal

Title: Bioorganic and Medicinal Chemistry Letters

Vol. 19

Pages: 6914-6917

ISSN: 0960-894X

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 19 Citations

Scopus - 19 Citations

Scientific classification

FOS: Medical and Health sciences

Other information

Authenticus ID: P-003-DK2

DOI: 10.1016/j.bmcl.2009.10.081

Abstract (EN): The growth inhibitory activity of imidazoquines, antimalarial imidazolidin-4-ones derived from primaquine, on human cancer cell lines HT-29, Caco-2, and MCF-7 has been evaluated. Primaquine, N-dipeptidyl-primaquine derivatives, and other quinolines have been included in the study for comparison purposes. Primaquine and some of its derivatives were significantly active against the MCF-7 human breast cancer cell line, so these compounds might represent useful leads targeted at the development of novel specific agents against breast cancer. Conversely, all compounds were generally inactive against HT-29, with only one of the imidazoquines having IC(50) below 50 mu M. Activities against the Caco-2 cell line were modest and did not follow any defined trend.

Language: English

Type (Professor's evaluation): Scientific